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Summary
Proof-of-concept studies have demonstrated the therapeutic
potential of engineered T cells. Transfer of recombinant anti-
gen-specific T cell receptors (TCR) and chimaeric antigen
receptors (CARs) against tumour and viral antigens are
under investigation by multiple approaches, including viral-
and nonviral-mediated gene transfer into both autologous
and allogeneic T cell populations. There have been notable
successes recently using viral vector-mediated transfer of
CARs specific for B cell antigens, but also reports of antici-
pated and unanticipated complications in these and other
studies. We review progress in this promising area of cellular
therapy, and consider developments in antigen receptor ther-
apies including the application of emerging gene-editing
technologies.
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Whilst the application of tyrosine kinase inhibitors and anti-
body-based therapies has become rapidly established in hae-
matological practice (Katsnelson, 2013), the use of cell-based
therapies, particularly genetically engineered T cells, is still
emerging. In recent months there have been a number of
encouraging reports detailing the therapeutic application of
genetically modified T cells. In particular, promising data
from trials investigating T cells modified to express chimaeric
antigen receptors (CARs) against B cell antigens have gener-
ated extensive interest from clinicians, researchers, pharma-
ceutical companies and investors (Humphries, 2013). Here
we review progress in this field, consider the technologies
involved and how these approaches are likely to be applied,
and the hurdles faced in delivering cell and gene therapies.
The potency of T cell-mediated immunity against viruses
and certain malignancies is now well established. In the
haematological setting, adoptive transfer of T cells against viral
pathogens, such as Epstein Barr Virus (EBV), Cytomegalovirus
(CMV) and Adenovirus, has been of proven benefit in the allo-
geneic stem cell transplant (allo-SCT) setting (Walter et al,
1995; Heslop et al, 1996, 2010; Peggs et al, 2003, 2011;
Cobbold et al, 2005; Feuchtinger et al, 2006; Leen et al, 2009;
Qasim et al, 2013a). Allogeneic T cells have been shown to
mediate graft-versus-leukaemia (GvL) effects following allo-
SCT, but these effects are offset by the risk of graft-versus-host
disease (GVHD) (Ho & Soiffer, 2001). Approaches to mitigate
against GVHD include expansion of T cell lines following anti-
genic stimulation with the aim of producing antigen-specific
populations while diminishing alloreactive clones. This can
take several weeks of culture but has been used to successfully
treat viral reactivation after transplant, and more recently to
treat leukaemic relapse (Chapuis et al, 2013). An alternative
approach to circumvent the need to culture, grow and enrich
T cells in this manner is to redirect T cell specificity through
the transfer of antigen receptor genes. These strategies may
involve recombinant variants of conventional heterodimeric
ab T cell receptor chains (TCR), or hybrid composites of anti-
body-like receptor chains linked to transmembrane and activa-
tion domains (CARs). Whereas abTCRs have lower affinities
and recognize processed peptide antigen expressed in the con-
text of major histocompatibility complex (MHC), CARs are
high affinity, MHC-unrestricted and capable of engaging target
cell surface proteins independently of presentation pathways
(Sadelain et al, 2013). Engineering T cells to express these
receptors has harnessed gene therapy technology, which
enables durable gene expression following viral vector-medi-
ated chromosomal integration of transgenes. Similar gamma-
retroviral (cRV) and lentiviral (LV) platforms have also been
used to engineer T cells for a variety of additional strategies.
For example, there is now two decades of experience using
cRV to express prodrug-activated suicide gene mechanisms
derived from Herpes Simplex Thymidine kinase (HSVTK) as a
contingency against GVHD, allowing elimination of mis-
matched T cells causing undesirable effects after allogeneic
transplantation through administration of ganciclovir (Bonini
et al, 1997). Preclinical studies have also shown that T cells can
be modified to resist agents such as ciclosporin (Brewin et al,
2009), potentially allowing preservation of selected functional
responses during periods of post-transplant immunosuppres-
sion and emerging technologies are exhibiting remarkable effi-
cacy in targeted gene disruption.
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In this article we update progress in the application of
genetically modified T cells. The technology and processes
involved in genetically modifying cells is reviewed, and recent
experience from early phase clinical trials summarized,
including anticipated and unanticipated adverse effects.
Finally, prospects for the wider application of existing
approaches are considered and emerging novel technologies
for gene editing and the targeted disruption of key receptors
reviewed.
Genetic modification of T cells
T cells have been attractive targets for gene modification for
almost three decades, being relatively easy to harvest and cul-
ture ex-vivo but researchers have encountered a variety of
hurdles. T cells are hard to transfect, and given their mitotic
properties, stable chromosomal integration of therapeutic
genes is required for sustained effects. Non-viral gene transfer
strategies have proven inefficient and require months of cell
culture and co-expression of drug selection genes to produce
usable yields of modified cells. In contrast, replication defec-
tive cRV derived from murine Moloney leukaemia virus have
been used to transduce T cells since the early 1990’s (Rosen-
berg et al, 1990; Ferrari et al, 1992; Mavilio et al, 1994) with
vectors devoid of packaging or envelope genes but retaining
intact retroviral long terminal repeat (LTR) promoter and
enhancer elements. These regions have been linked to inser-
tional mutagenesis in gene therapy trials of inherited
immune disorders where autologous haematopoietic stem
cells (HSC) were transduced ex-vivo and reinfused. In severe
combined immunodeficiency (SCIDX1) (Hacein-Bey-Abina
et al, 2003, 2008; Howe et al, 2008), Wiskott-Aldrich Syn-
drome (Braun et al, 2014), and Chronic Granulomatous dis-
ease (Ott et al, 2006); a number of subjects subsequently
developed T cell or myeloid leukaemias. However, there have
been no reports of similar genotoxicity in any clinical study
manipulating differentiated lymphocytes, and T cells have
been shown to resist retroviral-mediated transformation
(Newrzela et al, 2008). Data from longer term follow up
studies have tracked engineered T cells for over a decade in
patients and found no evidence of transformational effects
(Recchia et al, 2006; Scholler et al, 2012) and in extensive
pre-clinical modelling, there has only been a single report of
T cell transformation in a murine T cell study using cRV
(Heinrich et al, 2013). As well as cRV, alternative LV vector
systems, derived from attenuated forms of human immuno-
deficiency virus (HIV)-1 (Naldini et al, 1996; Dull et al,
1998; Demaison et al, 2002; Qasim et al, 2007) are now
being applied for T cell engineering. These vectors are gener-
ally considered less likely to mediate genotoxicity (Montini
et al, 2009) and can be designed to incorporate elements that
increase titre and gene expression (Dull et al, 1998; Zufferey
et al, 1999; Demaison et al, 2002). LV vectors can carry lar-
ger transgene cargos, are capable of stably transducing mini-
mally activated T cells and preferentially integrate in active
genes, without the bias towards transcription start sites
exhibited by cRV (Schroder et al, 2002).
One current advantage of cRV systems is the availability
of stable vector packaging cell lines (Miller & Buttimore,
1986), allowing for ready scalability of production, whereas
LV stocks are produced transiently, by transfection of multi-
ple plasmids into permissive cell lines. While LV studies are
now dominating gene therapy studies targeting HSC, it is
likely that both platforms will continue to be exploited for T
cell modification in the foreseeable future. Other viral vector
systems have had limited application for T cell therapies, but
Adenovirus has been used for transient episomal gene expres-
sion sufficient for T cell modification, as recently reported in
a study engineering T cells to resist HIV-1 (Tebas et al,
2014). One alternative non-viral vector system, derived from
mobile genetic elements and capable of chromosomal inte-
gration, is based on transposon transposition. Sleeping
beauty (Ivics et al, 1997) and PiggyBac (Ding et al, 2005)
transposons have been engineered to allow cut and paste
chromosomal integration of antigen receptor genes (Ivics &
Izsvak, 2011). Therapeutic genes can be delivered by electro-
poration in plasmid form, flanked by inverted repeat (IR)
and direct repeat (DR) sequences, which are then targeted by
the sleeping beauty transposase enzyme (delivered in trans
via a second plasmid). Excision and transposition of the IR/
DR flanked region results in non-biased insertion of the
sequence into genomic TA dinucleotide repeat sites. The
strategy has been compared to LV transduction of T cells
(Field et al, 2013) and could provide a more cost-effective
and streamlined approach to manufacturing, and the Sleep-
ing Beauty system has recently been used in early phase trials
of CAR19 T cell trials (see below) (Singh et al, 2014). Addi-
tional recent developments include transfer of therapeutic
genes in mRNA form, using the rationale that in certain situ-
ations, transient expression of therapeutic genes in T cells
may be sufficient for useful effects (Zhao et al, 2006). For
example, transient expression of DNA nucleases allows recep-
tor genes to be disrupted (see below) and non-sustained
antigen-specific CARs may be sufficient to reduce disease
burden in some conditions with a reduced risk of prolonged
cytokine storms or unexpected side effects.
Quiescent T cell are relatively refractory to genetic modifi-
cation and a variety of activation reagents have been used to
induce T cell division, including phytohaemagglutinin, OKT3
and magnetic beads conjugated with anti-CD3 and anti-
CD28 antibodies. Culture media are usually supplemented
with human serum and cytokines (usually interleukin-2, IL2)
and are capable of supporting T cell cultivation for several
weeks. Starting material may comprise autologous or human
leucocyte antigen (HLA) matched donor lymphocytes col-
lected by venesection or by non-mobilized peripheral blood
harvest. Whilst some protocols include steps to enrich CD4+
or CD8+ T cell subsets, or deplete CD4+ CD25+ regulatory T
cells, activation anti-CD3/anti-CD28 results in accumulation
of CD3 T cells to above 90% of cultures within 48–72 h and
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is currently the favoured method of activation. Transduction,
bead removal and enrichment (where required) of engineered
T cells under good manufacturing practice conditions is pos-
sible within the following 5 d, and readily yields sufficient
cells for infusion of over 107 cells/kg. Greater yields can be
recovered following extended culture periods of 2 weeks or
longer, but cells become prone to exhaustion and apoptosis.
Some trials have aimed to engineer virus-specific T cells
(Cruz et al, 2013) in which populations of T cells undergo
active expansion in response to challenge with autologous
presenting cells expressing viral antigens, although the pro-
cess can take several weeks or months.
Recent studies have investigated the optimal phenotype of
T cell populations for the most effective immunotherapy.
Effector memory cells can dominate cultures of transduced
cells, and exhibit reduced in vivo persistence (Berger et al,
2008). Longer-term persistence and function is provided by
central memory phenotype T cells, and na€ıve T cells retain
longer telomeres and the greatest proliferative potential
(Hinrichs et al, 2011). Recently, memory stem T cells have
attracted interest as populations with the greatest potential of
replication and expansion (Gattinoni et al, 2011). Targeted
transduction of these populations may offer an effective,
reduced cost approach to producing engineered T cells prod-
ucts. Whereas some early studies have aimed to infuse bil-
lions of engineered T cells following extended ex-vivo culture
and expansion, more recent reports (Table I) suggest dosing
in the range of 106–107/kg may be sufficient for therapeutic
effect with reduced risk of infusion-related toxicities. Impor-
tantly, experience of infusing allogeneic virus-specific T cells
against CMV and Adenovirus suggest that as few at 104 CD3
T cells/kg undergo in vivo expansion and are sufficient to
clear pathogens (Peggs et al, 2011; Qasim et al, 2013a).
Redirecting T cells to express ab
antigen-specific receptors
T cells recognize antigenic peptides in the context of HLA
molecules via highly diversified ab heterodimeric TCR, with
CD4 T cells recognizing MHC class 1 and CD8 T cells inter-
acting with MHC class II-presented peptide (Fig 1). The
TCR approach is limited to settings where TCR receptors
against specific tumour antigen petide/HLA-combinations
have been isolated from antigen-specific T cell clones. Retro-
viral transfer of genes encoding both the a and b TCR chains
for a receptor specific for the melanoma antigen MART1 was
the first to show efficacy in man. Engineered autologous T
cells mediated anti-tumour effects in clinical trials of
melanoma, with tumour regression in 2/15 subjects treated
(Morgan et al, 2006). Subsequent application of a higher
affinity TCR against MART1 resulted in responses in 6/20
patients but anticipated ‘on-target’ anti-melanin complica-
tions in skin, eyes and hair were encountered (Johnson et al,
2009). Side effects were also reported following infusion of
carcinoembryonic antigen-specific TCRs for colorectal carnci-
noma, where bowel inflammation developed after therapy
(Parkhurst et al, 2011). Minor toxicity was reported in
another study that targeted the cancer-testis antigen NY-
ESO-1 with notable tumour regression in patients with mela-
noma and synovial cell carcinoma (Robbins et al, 2011). In
the haematological setting, very few protein antigens have
proven suitable as targets for specific immunotherapy. While
common mutagenic proteins such BCR-ABL1 yield few use-
ful HLA-associated epitopes, certain otherwise normal pro-
teins may be aberrantly expressed on tumour cells. For
example, Wilms tumour antigen 1 (WT1) is expressed in leu-
kaemic cells including acute myeloid leukaemia (AML) and
myelodysplastic syndromes (MDS), at much higher levels
than in normal stem cells or other tissues. Clinical trials of
TCRs directed against HLA-A2/WT1 are being planned to
treat relapse of AML/MDS in centres in Japan (Ochi et al,
2011), the USA (Schmitt et al, 2013) and the UK (Xue et al,
2005) The approach is supported by data from a recent expe-
rience with (non-engineered) donor-derived WT1-specific
CD8 T cells infusions in post-transplant patients where antil-
eukaemic effects were detected without notable toxicities
(Chapuis et al, 2013).
A similar approach is being used to transduce donor-
derived T cells from CMV seronegative stem cell donors with
a HLA-A0201-restricted/CMV pp65-specific T cell TCR with
a view to treating transplant recipients who reactivate CMV
following the procedure. The strategy is being developed to
treat other viral complications including EBV (Hart et al,
2008), and has also been used to engineer autologous T cells
against Hepatitis B antigen for a patient with virus-related
hepatocellular carcinoma (Qasim et al, 2013b). These
approaches are attractive in mimicking native, physiological
TCRs with known activity against particular antigens, and
risks of aberrant effects through cross pairing of receptor
chains with endogenous receptors have been mitigated by
introducing additional disulphide bridges and the use of
murine constant chain domains in combination with human
TCR variable regions. However, the approach is constrained
in being HLA-restricted, and only a limited number of
tumour-specific antigens have been defined. Strategies to
modify TCR complimentarity determining regions (CDRs) to
enhance the affinity and avidity of abTCRs may address
some of these limitations, albeit with undefined, and difficult
to predict, risks of both ‘on-target’ and ‘off-target’ side
effects in normal host tissue. Recent trials of a HLA-A01
restricted, affinity enhanced MAGE-A3-specific TCR uncov-
ered serious toxicity with unexpected recognition of titin, a
cardiac petide antigen in subjects being treated for melanoma
and myeloma (Cameron et al, 2013; Linette et al, 2013).
These complications arose within days of therapy and despite
preclinical screening for possible cross-recognition of peptide
sequences and in vitro and in vivo toxicology experiments.
Similarly, unanticipated on-target neural complications have
arisen because of unappreciated MAGE expression in the
central nervous system (Morgan et al, 2013).
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T cells modified to express chimaeric
antigen-specific receptors
Chimaeric antigen receptors generally comprise an extracellu-
lar antibody-derived single chain antigen-recognition domain
linked to a transmembrane anchor and an intracellular sig-
nalling tail (Fig 1). The affinity of antigen binding afforded
by antibody-derived recognition is many fold stronger than
that mediated by conventional abTCRs, and CARs have the
advantage of not being HLA-restricted or dependent on anti-
gen processing and presentation (Table II). However, only a
limited number of tumour-specific targets have been defined
and chimaeric receptors are non-physiological and potentially
immunogenic. Transmembrane regions have been derived
from CD4 or CD8 and activation regions from elements of
CD3f in combination with CD27, CD28, 4-1BB, OX40 or
other costimulatory domains (reviewed recently) (Sadelain
et al, 2013). These receptors have evolved over three decades
from first generation, murine-derived receptors, to complex
third generation configurations with humanized sequences
which exhibit sustained in vivo persistence and antitumour
activity against B cell malignancies (Table I), neuroblastoma,
(Park et al, 2007; Pule et al, 2008; Louis et al, 2011) ovarian
(Kershaw et al, 2006) and renal carcinomas (Lamers et al,
2011). The consequences of introducing additional costimu-
latory domains into second generation CARs have been
directly compared against first generation configurations in
subjects with B cell lymphomas who were infused with two
autologous CD19-specific CAR-modified therapies. One
included both a costimulatory CD28 and the CD3f activation
domain, while the other encoded only the CD3f domain.
The second generation configuration supported longer in
vivo persistence and responses in 2/6 subjects with non-
Hodgkin lymphoma (Savoldo et al, 2011). Preclinical data
comparing different constimulatory configurations suggested
that 4-1BB signalling domains exhibited a reduced propensity
to trigger IL2 and tumour necrosis factor a (TNFa) secretion
(and thus precipitate cytokine release syndromes) compared
to CD28 signalling domains (Milone et al, 2009). This has
been supported by early clinical data from studies using the
Table I. Recent gamma-retroviral and lentiviral trials of CAR T cell therapy against CD19.
Centre Vector and CAR configuration Patients/disease Conditioning, dosing Complications Outcome References
UPENN LV
4-1BB, CD3f
3 CLL Autologous with
conditioning
Cyclophosphamide
Pentostatin
Bendamustine
Dose:105–107/kg
Tumour lysis
syndrome
2 CR,
1 PR
Grupp et al (2013)
Kalos et al (2011)
Porter et al (2011)
2 ALL Autologous
1 conditioned
Cyclophoshamide
Etoposide
1 unconditioned
Dose: 106–107/kg
Cytokine release
syndrome
B cell aplasia
2 CR,
1 durable
NCI RV
CD28, CD3f
8 B lymphomas Cylophosphamide
Fludarabine
Dose: 106–107/kg
Tumour lysis 6 remission Kochenderfer et al (2013)
Kochenderfer et al (2012)
Kochenderfer et al (2010)
10 post-SCT Allogeneic post-HSCT
Unconditioned
Hypotension
Fever
B cell aplasia
3 regression
MSKCC RV
CD28, CD3f
8 CLL
1 ALL
Unconditioned or
Cyclophosphamide
Dose: 106–107/kg
Death
B cell aplasia
1 response Brentjens et al (2013)
Brentjens et al (2011)
Davila et al (2014)
5 ALL Cyclophosphamide
Dose: <3 9 106/kg
Cytokine release
syndrome
5 MRD
Baylor RV
CD28, CD3f
8 allo-SCT Unconditioned 2 responses Cruz et al (2013)
RV
CD3f
CD28, CD3f
6 NHL Unconditioned
Dose: <109/m2
2 responses Savoldo et al (2011)
UPENN, University of Pennsylvania; NCI, National Cancer Institute; MSKCC, Memorial Sloan Kettering Cancer Center; CAR, chimaeric antigen
receptor; LV, lentiviral; RV, retroviral; CLL, chronic lymphocytic leukaemia; ALL, acute lymphoblastic leukaemia; NHL, non-Hodgkin lymphoma;
SCT, stem cell transplantation; HSCT, haemopoietic stem cell transplantation; CR, complete response; PR, partial response; MRD, minimal resid-
ual disease.
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4-1BB regions where there has been has been a suggestion of
favourable clinical outcomes (Kalos et al, 2011) but direct
comparisons in individual patients are lacking.
Overall, targeting cell surface marker molecules expressed
on the majority of B-cell malignancies (and absent on unre-
lated tissues) has yielded the most promising clinical results.
A number of early trials used electroporation to deliver plas-
mids encoding first generation anti-CD20 CARs with CD3f
activation domains linked to antibiotic resistance/drug selec-
tion genes. Extended ex-vivo culture (for several months) was
required to generate target cells doses in excess of 109/kg,
which were administered after conditioning with cyclophos-
phamide or fludarabine (Till et al, 2008; Jensen et al, 2010).
Use of cRVs expressing second-generation anti-CD19 CARs
with CD3f and CD28 activation domains mediated clinical
responses in 6/8 patients with B cell malignancies (including
chronic lymphocytic leukaemia [CLL] and follicular lym-
phoma) (Kochenderfer et al, 2010, 2012). The trial used
OKT3 (anti-CD3) and IL2 for autologous T cell activation
and cultured cells for over 3 weeks, before administration of
cells doses up to 3 9 107/kg following lymphodepletion with
cyclophosphamide or fludarabine. The same group also pub-
lished data from 10 subjects who received infusions (without
conditioning) of up to 78 9 106 cells/kg allogeneic donor T
cells following allo-SCT for a variety of B cell malignancies
that had persisted after conventional donor lymphocyte infu-
sions. Three patients had disease regression and no patients
developed GVHD although B cell aplasia was reported (Koc-
henderfer et al, 2013). Similarly modified allogeneic T cells
were also used in a trial reported by researchers at Baylor,
where eight subjects received cells transduced and cultured
following activation by co-culture with EBV-transformed
lymphoblastoid cell lines (Cruz et al, 2013). Again, there was
no problematic GVHD but a number of subjects developed
B cell lymphopenia. In the autologous setting, Memorial
Sloan Kettering Cancer Center researchers have investigated
similar second generation configurations, using gRV and ex-
vivo transduction following activation with anti-CD3/28
beads, and included pre-conditioning with cyclophosphamide
in some patients (Brentjens et al, 2011, 2013). A number of
responses were documented and B cell aplasia reported.
Some of the most promising data to date has been published
by investigators at the University of Pennsylvania. Here, LV
delivery of second generation CARs (with CD3f and 4-1BB
domains) was combined with patient conditioning with com-
binations of cyclophosphamide, bendamustine, penotatsin
and etoposide in patients with CLL and acute lymphoblastic
leukaemia (ALL) (Kalos et al, 2011; Porter et al, 2011; Grupp
et al, 2013). Treatment was associated with remission of CLL
and acute toxicities included macrophage activation syn-
dromes and ‘cytokine storms’ as discussed below. All three
CLL patients developed B cell aplasia, an expected conse-
quence of anti-CD19 therapy. The investigators calculated
effector:target cell ratios in these patients and estimated that
in vivo T cell expansion greater than 1000-fold contributed
to antileukaemic effects through serial killing effects. One of
the two paediatric patients treated for ALL using autologous
CAR19-modified T cells subsequently relapsed after
2 months with circulating CD34+ CD45+dim CD19 blasts,
suggesting T cell-driven selective pressure allowing emergence
of CD19 populations. This type of tumour escape phenom-
Table II. Comparison of TCR and CAR antigen-specific receptors.
Recombinant ab TCR Chimaeric antigen receptors
Cloned human TCR a and b variable regions
Human or murine constant regions
Additional disulphide bridge to prevent cross pairing with endogenous chains
Antibody-derived variable and constant regions
Composite spacer, transmembrane and signalling domains
Recognize processed peptide in context of HLA Recognize cell surface proteins independently of MHC
processing or presentation
Low affinity binding High affinity binding
Physiological signalling via the endogenous CD3 complex Non-physiological, ectopic, CD3f activation
MHC, major histocompatibility complex; TCR, T cell receptor; CAR, chimaeric antigen receptor; HLA, human leucocyte antigen.
Fig 1. T cells engineered to express antigen-specific receptors can
recognize and eliminate leukaemic cells. The ab T cell receptor
(TCR) comprises a heterodimer that can be engineered to prevent
cross-pairing with endogenous TCR chains, and is expressed in asso-
ciation with signalling chains of the CD3 complex. TCRs recognize
specific antigenic peptides that have been processed and presented in
association with human leucocyte antigen (HLA) molecules
expressed on the surface of target cells. Chimaeric antigen receptors
are hybrid composites derived from the antigen binding domains of
antibodies, linked to CD3f activation domains and costimulatory
moieties via transmembrane bridges. These receptors mediate high
affinity binding of target cell surface proteins and are independent of
HLA presentation. CAR, chimaeric antigen receptor; MHC, major
histocompatibility complex.
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enon highlights an important limitation of targeting a single
antigen, but also provides a rationale for simultaneously tar-
geting additional antigens, such as CD20 and CD22 in B cell
malignancies. In relapsed myeloid malignancies CD30 and
CD33 may provide suitable targets, but may also be prob-
lematic if there is associated depletion of myeloid progenitors
and stem cell populations. Alternative tumour-associated
antigens with wider applicability include Lewis Y (LeY), a
difucosylated carbohydrate antigen, which has poorly defined
functions, but is expressed on a wide range of malignancies,
including certain forms of AML, but has only limited expres-
sion on normal tissue. Australian investigators coupled a
CAR specific for LeY to cytoplasmic domains of CD28 and
the CD3-f chain and have undertaken an initial safety study
in patients with relapsed AML, where blasts were known to
express LeY (Ritchie et al, 2013). Conditioning comprised
fludarabine and four patients received up to 13 9 109 T
cells without significant toxicity. Cytogenetic remission was
achieved in one patient and protracted remission in another.
Interestingly, In111-labelled CAR T cells could be tracked in
vivo, and were shown to traffic to the bone marrow using
single photon emission computed tomography (SPECT)
imaging. Experience form allogeneic transplantation suggests
certain anatomical sites may provide sanctuary against
immune-mediated anti-leukaemic effects and the effectiveness
of cellular immunotherapy against extra-medullary tumours,
including testicular relapse or central nervous system (CNS)
disease, has yet to be elucidated. Nonetheless, EBV-specific T
cells can track to extramedullary sites of EBV-lymphoprolif-
erative disease (Heslop et al, 2010) and early trial reports
suggest successful responses linked to the presence of CD19
CAR-modified T cells in cerebrospinal fluid in patients with
CNS leukaemic relapse (Lee et al, 2013).
Whilst initial non-viral approaches based on plasmid
transfer were inefficient, more recently trials have com-
menced at the MD Anderson Cancer Center in Texas using a
Sleeping Beauty transposase system for first-in-man studies.
Second generation CAR19 constructs, under the control of
the human EF1a promoter and flanked by IR/DR transposi-
tion target sequences are being used in trials of autologous
and alloegenic trials against B cell malignancies (Singh et al,
2014). The approach requires longer periods of ex-vivo cul-
ture compared to viral vector strategies, but is potentially
more flexible for switching between different receptor and
activation domain configurations.
Conferring drug sensitivity and resistance
A number of trials have established the feasibility of using T
cells engineered to be sensitive to particular drugs by inclu-
sion of a ‘suicide gene’ mainly using the viral HSVTK gene
linked to selection genes for antibiotic (e.g., Neomycin resis-
tance) or magnetic bead selection (e.g., truncated forms of
the low affinity nerve growth factor receptor) (Bonini et al,
1997; Tiberghien et al, 2001; Burt et al, 2003; Ciceri et al,
2007, 2009). Such cells have been administered following
mismatched or halpoidentical transplantation and trials orig-
inally initiated two decades ago in Milan have reported
improved immune reconstitution and control of GVHD by
using ganciclovir in a number of subjects (Bonini et al, 1997;
Tiberghien et al, 2001; Burt et al, 2003; Ciceri et al, 2007,
2009). To facilitate enrichment of suicide gene engineered
cells, HSVTK has also been fused to a splice variant of
human CD34, which enables rapid CliniMacs-based selection
of transduced cells (Zhan et al, 2013). Although HSVTK
encodes a virally-derived protein and immune responses
against engineered cells have been detected, longer-term per-
sistence has also been reported. An alternative inducible
switch, based on a fusion of human caspase-9 and a variant
human FK-binding protein has also been tested in pilot stud-
ies (Di Stasi et al, 2011). Here, suicide gene expression was
linked to truncated CD19 for cell enrichment. Administra-
tion of a synthetic dimerizing drug activated caspase-medi-
ated apoptosis of transduced cells. Similarly, expression of
CD20, which can be targeted by rituximab, offers another
potential avenue for targeted T cell elimination and is under-
going preclinical evaluation. Whilst these approaches have
been developed primarily to allow infusion of polyclonal T
cells populations whilst protecting against the risk of GVHD
in allo-SCT, it is possible that they will also be included in
vectors expressing novel antigen-specific receptors to safe-
guard against adverse effects in the autologous setting.
There have also been attempts to render T cells resistant
to immunosuppressive agents, and such cells could have
interesting niche applications. For example, adoptive transfer
of EBV-specific T cells is an effective treatment for EBV-
related lymphoproliferative disease but post-transplant
immunosuppression following solid organ grafting can
impair effective cellular responses. Calcineurin mutants have
been designed to confer resistance to one or both of the
commonly used immunosuppressants, tacrolimus and ciclo-
sporin (Brewin et al, 2009; Ricciardelli et al, 2013) and pro-
posals for pilot studies are being developed. Other
approaches include rendering cells insensitive to steroids
through nuclease-mediated disruption of the glucocorticoid
receptor in T cells, and resistance against mycophenol phe-
nolate through expression of mutant inosine monophosphate
dehydrogenase (Yam et al, 2006; Sangiolo et al, 2007).
Host preparation and managing adverse effects
Engraftment, persistence and efficacy of engineered T cells is
enhanced by the use of preparative conditioning of patients.
Agents, such as cyclophosphamide, fludarabine, pentastatin
and low dose irradiation, or serotherapy are all capable of
mediating lymphodepletion without myeloablation. Each
approach has specific related toxicities, but all increase the
risk of viral reactivation and other infectious complications.
Nonetheless, in the conditioned lymphopenic host, T cells
undergo homeostatic expansion and are less prone to the
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immunosuppressive effects mediated by host regulatory T
cells. Furthermore, elimination of host lymphocytes reduces
the risk of host-mediated immune responses against the engi-
neered cells that could lead to rejection, especially if encoded
receptors or other transgenes include non-human or novel
protein sequences. There is currently little trial data compar-
ing the intensity of conditioning required for effective
responses, and larger studies with optimal vector-receptor
configurations are required to determine the most suitable
preparative regimens.
Post-infusion toxicities and side effects can be considered
as immediate, infusion-related events and longer term
expected or unexpected consequences. Early cytokine release
syndrome (CRS) in CAR therapies has been related to multi-
ple factors including c-interferon (IFNc, TNFa, IL1, IL2 and
IL6, and may contribute to anti-leukaemic effects, but conse-
quential inflammation and macrophage activation syndrome
(MAS) can mimic sepsis with hypotension, fever rigours and
vascular leak syndromes (Brentjens et al, 2013). Management
has included supportive care and the use of methylpredniso-
lone as well as a variety of monoclonal antibody therapies,
including etanercept targeting TNFa and tocilizumab target-
ing the IL6 receptor. Differentiation from tumour lysis syn-
drome or bacterial sepsis may be complex, necessitating
multiple therapeutic approaches. Davila et al (2014) recently
proposed diagnostic criteria defining CRS based on the pres-
ence of fever, hypotension, hypoxia or the development of
neurological complications in association with a 75-fold rise
in serum levels of two relevant cytokines. It is plausible that
the risk of precipitating CRS may be mitigated by reducing T
cell doses, or by administration of multiple, smaller dose
aliquots, and by dose escalation strategies. As more data
accumulates it may also be possible to identify cytokine gene
polymorphisms that predispose to exaggerated inflammatory
responses. Finally, a longer-term and expected consequence
of using CAR therapy targeting B cell antigens has been B
cell aplasia and the need for replacement immunoglobulin
therapy, although this is relatively straightforward to manage.
Emerging tools for T cell engineering
Emerging strategies are being investigated for gene-editing
rather than conventional gene-addition approaches. Molecu-
lar reagents capable of mediating highly specific DNA cleav-
age using targeted nucleases are providing a variety of new
possibilities. Examples include zinc finger nucleases (ZFNs)
(Urnov et al, 2005; Lombardo et al, 2007), transcription acti-
vator-like effector nucleases (TALENs)(Miller et al, 2011)
and clustered regularly interspaces short palindromic repeats
(CRISPR) reagents (Jinek et al, 2012; Cong et al, 2013; Mali
et al, 2013) and all are under investigation for a broad spec-
trum of gene therapy applications. Each have specialized
DNA binding elements linked to nuclease enzymes capable of
DNA scission (Fig 2). One early example of clinical applica-
tion is the recent use of ZFNs targeting the CCR5 gene locus
in trials aiming to disrupt expression of the HIV co-receptor
in T cells from subjects with the infection (Tebas et al,
2014). Similarly, ZFNs and TALENs have been used to dis-
rupt expression of endogenous T cell receptors in pre-clinical
studies demonstrating the feasibility of generating T cells
devoid of alloreactive TCRs by targeting the constant region
of the TCR a and/or b chain (Provasi et al, 2012). Introduc-
tion of antigen-specific receptors into such cells could yield
populations of ‘universal T cells’ that are suitable for infu-
sion (following conditioning) into multiple HLA disparate
recipients without the risk of GVHD (Torikai et al, 2012).
Similar reagents are being developed to render T cells ‘invisi-
ble’ to a commonly used conditioning antibody, alemtuze-
mab. By disrupting CD52 expression, T cells rendered
insensitive to depletion by alemtuzemab and could be
infused immediately following serotherapy-conditioned trans-
plant procedures, allowing exploitation of anti-viral or anti-
leukaemia effects. Similarly, disruption of disparate HLA
molecules on donor T cells may provide mitigation against
host-mediated rejection (Torikai et al, 2013). For these appli-
cations, transient expression of DNA modifying nuclease
reagents in T cells is desirable (rather than integrated, perma-
nent gene insertion) and thus electroporation of mRNA and
may be sufficient for therapeutic effect. The availability of
next generation high throughput sequencing will facilitate
screening for off-target genomic effects including undesirable
chromosomal effects resulting in translocations, rearrange-
ments or deletions, which necessitate careful characterization
and monitoring.
Fig 2. Molecular tools for gene editing are evolving and can mediate
highly specific cleavage of double stranded DNA at an efficiency that
is sufficient to be therapeutically useful. Zinc finger nucleases (ZFNs)
are already being evaluated for disruption of the Human immunode-
ficiency virus co-receptor CCR5 in T cells. In common with alterna-
tive reagents based on transcription activator-like effector nucleases
(TALENs), scission relies on dimerization of Fok1 endonucleases at
defined genomic target sites. Recently, RNA-based DNA targeting
reagents called clustered regularly interspaced short palindromic
repeats (CRISPRs) have become available, and here, DNA cleavage is
mediated by the enzyme Cas9. These reagents open up the possibility
of designer T cells with multiple genetic modifications in combina-
tion with introduced receptors and safety/selection genes.
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Delivering T cells beyond trials
Harvest, isolation, activation, transduction, expansion, selec-
tion and cryopreservation of patient-derived T cells to pro-
duce bespoke medicinal therapies requires notable
infrastructure and expertise. Currently only a small number
of centres worldwide can provide such therapies, and gener-
ally only as part of a structured clinical trial. Notable bottle-
necks include limited vector production capacity for cRV or
LV vector stocks and difficulties in scaling production for
larger trials. Differences between European and other regula-
tory jurisdictions provides challenges for the implementation
of multicentre clinical trials and ultimately the development
of licensed medicinal products, although there is increasing
dialogue aimed at addressing these issues. Wider deployment
will also require a notable investment in addressing the logis-
tics of harvesting, engineering and returning T cells to
patients. There are, of course, established procedures and
pathways for the harvest and infusion of bone marrow and
peripheral blood stem cell products and networked trans-
plant centres, which are well placed to deliver T cell therapies
if manufactured, cryopreserved and shipped from a central
processing hub. In recent months there has been considerable
interest and investment from pharmaceutical companies aim-
ing to establish strategic partnerships with leading research
centres. Novartis, Celgene, Juno Therapuetcis, BlueBird Bio
and others are all aiming to commercialize CAR therapies,
and Kite Pharma and Adaptimmune are amongst companies
pursuing abTCR-based therapies (Humphries, 2013). There
could be rapid dissemination of CAR19-based therapies if
the logistical issues are addressed, and a broadening of early
phase trials assessing a variety of other target antigens in
both haematological and other malignancies should follow.
The implications for health care purchasers and providers
have yet to unfold, but pricing is likely to attract a premium
if single episode cell therapies can offer the possibility of
durable benefit or cure.
Summary
Experience from studies using engineered T cells, including
cells expressing chimaeric antigen-specific receptors, are pro-
viding proof of concept data for an emerging area of cellular
therapy. Related vector platforms are being used to confer
drug sensitivity and resistance, and emerging technologies are
promising more sophisticated designer gene engineered T
cells. Larger multi-centre trials will needed to determine
which particular therapies offer the most effective interven-
tions, and this in turn will require and number of technical
and logistical hurdles to be addressed. Nonetheless, large
investments are being proffered to accelerate clinical applica-
tion, and prospects for T cell therapies look interesting.
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